



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
1100 East William Street, Suite 101  
Carson City, Nevada 89701  
Telephone (775) 684-3676 • Fax (775) 687-3893  
<http://dhcfp.nv.gov>

## NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

**Date of Posting:** September 13, 2019  
**Date of Revision:** September 17, 2019

**Date of Meeting:** October 17, 2019 at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

**Place of Meeting:** Hyatt Place Reno -Tahoe Airport  
1790 E Plumb Ln  
Reno, NV 89502  
Phone: (775) 826-2500

**Webinar Registration:** <https://optum.webex.com/optum/onstage/g.php?MTID=e78d290166063056ec16813fcca8f0461>

Or go to [www.webex.com](http://www.webex.com) and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

**Event Number:** 644 285 791

Click “Join Now”

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

A password should not be necessary, but if asked use:  
Medicaid1!

For Audio Only:

Phone: 1-763-957-6300  
Event: 644 285 791

## AGENDA

1. **Call to Order and Roll Call**
2. **Public Comment on Any Matter on the Agenda**
3. **Administrative**
  - a. **For Possible Action:** Review and approve meeting minutes from July 25, 2019
  - b. Status Update by the DHCFP
    1. Proclamation by Governor Sisolak in recognition of International Overdose Awareness Day.
    2. ~~Impact of AB-474 report.~~ Statistics related to opioid prescriptions rates, number of potential “doctor shoppers,” number of Prescription Monitoring Program (PMP) queries and number of individuals co-prescribed benzodiazepines and opioids.
    3. DHCFP policy updates.
4. **Clinical Presentations**
  - a. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for Zolgensma (onasemnogene abeparvovec-xioi)
    1. Public comment on proposed clinical prior authorization criteria.
    2. Presentation of utilization and clinical information.
    3. Discussion by Board and review of utilization data.
    4. Proposed adoption of updated prior authorization criteria.
  - b. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for narcolepsy agents
    1. Public comment on proposed clinical prior authorization criteria.
    2. Presentation of utilization and clinical information.
    3. Discussion by Board and review of utilization data.
    4. Proposed adoption of updated prior authorization criteria.
  - c. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for hematopoietic/hematinic agents
    1. Public comment on proposed clinical prior authorization criteria.
    2. Presentation of utilization and clinical information.

3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- d. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Regranex (becaplermin)
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for topical, local anesthetics
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- f. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for inhaled anticholinergic agents
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- g. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Daliresp (roflumilast)
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- h. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for topical antiparasitics
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.
- i. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for topical immunomodulators
1. Public comment on proposed clinical prior authorization criteria.
  2. Presentation of utilization and clinical information.
  3. Discussion by Board and review of utilization data.
  4. Proposed adoption of updated prior authorization criteria.

- j. **For Possible Action:** Presentation, discussion and possible adoption of updated DUR Bylaws
  - 1. Presentation by the DHCFP of updates to DUR Bylaws
  - 2. Discussion by Board and review of updates to DUR Bylaws
  - 3. Proposed adoption of updated DUR Bylaws.

## 5. DUR Board Requested Reports

- a. Opioid utilization – top prescribers and members
  - 1. Discussion by the Board and review of utilization data.
  - 2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- b. Top opioid prescribers and top benzodiazepine prescribers
  - 1. Discussion by the Board and review of utilization data.
  - 2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- c. Lock-in program
  - 1. Discussion by the Board and review of utilization data.
  - 2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- d. Naloxone utilization in members receiving opioids
  - 1. Discussion by the Board and review of utilization data.
  - 2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- e. Aranesp (darbepoetin alfa) utilization
  - 1. Discussion by the Board and review of utilization data.
  - 2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.
- f. Antibiotic (third generation cephalosporins, fluoroquinolones and oxazolidinones) utilization
  - 1. Discussion by the Board and review of utilization data.
  - 2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.

## 6. Standard DUR Reports

- a. Review of Prescribing/Program Trends.

1. Top 10 Therapeutic Classes for first quarter 2019 and second quarter 2019 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
  1. Review of second quarter 2019.
  2. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
  1. Status of previous quarter.
  2. Status of current quarter.
  3. Review and discussion of responses.

## 7. Closing Discussion

- a. Public comments on any subject.
- b. Date and location of the next meeting.
  1. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to five minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and <http://notice.nv.gov/>, Carson City Central Office, Reno District Office, Elko District Office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least three days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by

e-mail at [tbenitez@dchfp.nv.gov](mailto:tbenitez@dchfp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730.